Recent insights into cutaneous immunization: How to vaccinate via the skin

Engelke, Laura; Winter, Gerhard; Hook, Sarah; Engert, Julia

doi:10.1016/j.vaccine.2015.05.012

Cited by 89 publications

(80 citation statements)

References 203 publications

(292 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of APCs initiating adaptive immune responses, such as Langerhans cells and dermal dendritic cells in the epidermis and dermis, was higher than that in SC tissues or muscles [9,29], suggesting that TD vaccination induces an antibody response to a lower dose of antigens than SC vaccination. Consistent with these findings, MN vaccination with WVP and SV prepared from H1 and H5 influenza viruses showed higher potency than SC vaccination.…”

Section: Discussionmentioning

confidence: 97%

“…The epidermis and dermis contain a large population of resident antigen-presenting cells (APCs) and are considered to be active immune tissues [9]. Recently, various vaccination methods targeting these tissues have been developed and occasionally demonstrated to be better than subcutaneous (SC) injections, e.g., powder injection, electroporation, sonoporation, jet injection, mini needle injection, and microneedle (MN) injection [10][11][12][13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice

Nakatsukasa

Kuruma

Okamatsu

et al. 2017

Vaccine

View full text Add to dashboard Cite

Transdermal vaccination using a microneedle (MN) confers enhanced immunity compared with subcutaneous (SC) vaccination. Here we developed a novel dissolving MN patch for the influenza vaccine. The potencies of split virion and whole virus particle (WVP) vaccines prepared from A/Puerto Rico/8/1934 (H1N1) and A/duck/Hokkaido/Vac-3/2007 (H5N1), respectively, were evaluated. MN vaccination induced higher neutralizing antibody responses than SC vaccination in mice. Moreover, MN vaccination with a lower dose of antigens conferred protective immunity against lethal challenges of influenza viruses than SC vaccination in mice. These results suggest that the WVP vaccines administered using MN are an effective combination for influenza vaccine to be further validated in humans.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice

Nakatsukasa

Kuruma

Okamatsu

et al. 2017

Vaccine

View full text Add to dashboard Cite

show abstract

“…These methods disrupt the stratum corneum layer and help to deliver the antigen into the skin, and they have also been investigated for delivery of antigens across the skin [203–205]. …”

Section: Mucosal Vaccine Delivery Systemsmentioning

confidence: 99%

Mucosal vaccine delivery: Current state and a pediatric perspective

Shakya

Chowdhury

Tao

et al. 2016

Journal of Controlled Release

127

115

View full text Add to dashboard Cite

Most childhood infections occur via the mucosal surfaces, however, parenterally delivered vaccines are unable to induce protective immunity at these surfaces. In contrast, delivery of vaccines via the mucosal routes can allow antigens to interact with the mucosa-associated lymphoid tissue (MALT) to induce both mucosal and systemic immunity. The induced mucosal immunity can neutralize the pathogen on the mucosal surface before it can cause infection. In addition to reinforcing the defense at mucosal surfaces, mucosal vaccination is also expected to be needle-free, which can eliminate pain and the fear of vaccination. Thus, mucosal vaccination is highly appealing, especially for the pediatric population. However, vaccine delivery across mucosal surfaces is challenging because of the different barriers that naturally exist at the various mucosal surfaces to keep the pathogens out. There have been significant developments in delivery systems for mucosal vaccination. In this review we provide an introduction to the MALT, highlight barriers to vaccine delivery at different mucosal surfaces, discuss different approaches that have been investigated for vaccine delivery across mucosal surfaces, and concludes with an assessment of perspectives for mucosal vaccination in the context of the pediatric population.

show abstract

“…For example, prior studies have shown dose sparing, longer-lived immune responses, greater breadth of immunity, isotype class switching and other immunologic advantages and differences when vaccinating in skin using MNPs as opposed to IM or subcutaneous injection. 13,14 While microneedles do not typically insert fully into skin due to skin surface deformation, prior studies indicate that insertion is sufficient to access both epidermis and at least superficial dermis, thereby accessing Langerhans cells and dermal dendritic cells, respectively. 15 In this work, we use the term "intradermal" immunization to refer to stratum corneum puncture accompanied by delivery of vaccine into the epidermis and dermis.…”

mentioning

confidence: 99%

Hepatitis B vaccination using a dissolvable microneedle patch is immunogenic in mice and rhesus macaques

Kodani

Choi

et al. 2018

Bioengineering & Transla Med

View full text Add to dashboard Cite

Chronic Hepatitis B virus infection remains a major global public health problem, accounting for about 887,000 deaths in 2015. Perinatal and early childhood infections are strongly associated with developing chronic hepatitis B. Adding a birth dose of the hepatitis B vaccine (HepB BD) to routine childhood vaccination can prevent over 85% of these infections. However, HepB BD coverage remains low in many global regions, with shortages of birth attendants trained to vaccinate and limited HepB BD supply at birth. To address the challenges, we developed coated metal microneedle patches (cMNPs) and dissolvable microneedle patches (dMNPs) that deliver adjuvant‐free hepatitis B vaccine to the skin in a simple‐to‐administer manner. The dMNP contains micron‐scale, solid needles encapsulating vaccine antigen and dissolve in the skin, generating no sharps waste. We delivered HepB BD via cMNP to BALB/c mice and via dMNP to both mice and rhesus macaques. Both cMNP and dMNP were immunogenic, generating hepatitis B surface antibody levels similar to human seroprotection. Biomechanical analysis showed that at high forces the microneedles failed mechanically by yielding but microneedles partially blunted by axial compression were still able to penetrate skin. Overall, this study indicates that with further development, dMNPs could offer a method of vaccination to increase HepB BD access and reduce needle waste in developing countries.

show abstract

Recent insights into cutaneous immunization: How to vaccinate via the skin

Cited by 89 publications

References 203 publications

Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice

Potency of whole virus particle and split virion vaccines using dissolving microneedle against challenges of H1N1 and H5N1 influenza viruses in mice

Mucosal vaccine delivery: Current state and a pediatric perspective

Hepatitis B vaccination using a dissolvable microneedle patch is immunogenic in mice and rhesus macaques

Contact Info

Product

Resources

About